alexa Hodgkin's Disease: Past to Present | Open Access Journals
ISSN: 2165-7831
Journal of Blood & Lymph
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Hodgkin's Disease: Past to Present

Priyanka Pathak*

Physician, Kimmel Cancer Center, Department of Medical Oncology, Thomas Jefferson University, PA, USA

*Corresponding Author:
Priyanka Pathak, MD, MPH
Physician, Kimmel Cancer Center
Department of Medical Oncology
Thomas Jefferson University
111 S. 11th St, Philadelphia, PA 19107, USA
Tel: 281-536-9472

Received date: March 28, 2015; Accepted date: March 30, 2015; Published date: April 10, 2015

Citation: Pathak P (2015) Hodgkin’s Disease: Past to Present. J Blood Lymph 5:e118. doi: 10.4172/2165-7831.1000e118

Copyright: © 2015 Pathak P, This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Blood & Lymph


Hodgkin’s disease (HD) is an uncommon malignancy accountingfor an incidence of 0.6% of all cancers. In 2015, an estimated 9,050people will be diagnosed with HD in the United States and 1,150people will die from the disease [1]. From 2007 to 2011, the incidencerates for HD have been stable but death rates have been steadilydecreasing by 2.2% per year for men and 2.7% for women per year forwomen. The latter have been attributed to better therapeutic interventions.

Once considered, the “inexorably fatal condition”, HD had long beena subject of controversy with respect to its nature, etiology and therapy.Initially thought to be an infectious disease due to its association withtuberculosis, definitive evidence of its neoplastic nature came in the1960’s when cytogenetic studies confirmed its clonal derivation and aneuploidy.

The contiguous nature of its spread via lymphatic channels whichwas demonstrated when laparotomy was used as a staging tool at theStanford University Medical Center for the first time in 1969, changedprevailing ideas of its treatment from essentially symptomatic tocurative [2]. Treatment of HD has been fraught with controversy,ranging from surgical approaches which are no longer used,radiotherapy (extended field radiation versus involved field radiation) and chemotherapy (single versus multidrug regimens).

This disease has served as a model for the development of combinedmodality therapy with a multidisciplinary approach involvingradiation oncologists, medical oncologists and radiologists. It has alsoserved as the basis for interim PET/CT scans in the prognostication ofother lymphomas and its treatment started the era of multi-agent chemotherapy for other hematologic malignancies.

HD has also been instrumental in the designing of long term studieswhich enables the assessment of the long-term effects of a treatmentand helps us seek a balance between treatment effectiveness and theavoidance of long term gonadal, cardiac and secondary neoplastic complications.

Currently, the standard of care for previously untreated HD in theUnited States is combined modality therapy for Stage I and Stage IIdisease and combination chemotherapy (ABVD, Stanford V andBEACOPP) for advanced stages [3]. The 5 year survival rates for HDrange from 90.8% for localized disease to 76.2% for distant disease [4].Thus, we have come a long way from a potentially fatal disease to an imminently curable one.

In this issue, Salvatore et al. present a case of a 44 year old womanwho presented with a bulky Stage II Hodgkin’s lymphoma withmediastinal syndrome. The patient had been aware of the tumor forabout three years prior to her admission. This case report showcases afew important details- namely the natural history of Hodgkin’s diseasewhich is rare with current medical advances, the effectiveness ofcurrent treatments and the social stigma of cancer which prevented her from seeking medical treatment leading to the fatal outcome.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 11528
  • [From(publication date):
    April-2015 - Jul 28, 2017]
  • Breakdown by view type
  • HTML page views : 7786
  • PDF downloads :3742

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

1-702-714-7001Extn: 9037

Business & Management Journals


1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

1-702-714-7001 Extn: 9042

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version